GR3026612T3 - Hepatitis a virus strain, method for the isolation of said virus strains and hepatitis a vaccines - Google Patents
Hepatitis a virus strain, method for the isolation of said virus strains and hepatitis a vaccinesInfo
- Publication number
- GR3026612T3 GR3026612T3 GR980400808T GR980400808T GR3026612T3 GR 3026612 T3 GR3026612 T3 GR 3026612T3 GR 980400808 T GR980400808 T GR 980400808T GR 980400808 T GR980400808 T GR 980400808T GR 3026612 T3 GR3026612 T3 GR 3026612T3
- Authority
- GR
- Greece
- Prior art keywords
- hepatitis
- havs
- relates
- virus
- vaccines
- Prior art date
Links
- 241000709721 Hepatovirus A Species 0.000 title abstract 9
- 238000002955 isolation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 abstract 2
- 230000001900 immune effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1009—Picornaviridae, e.g. hepatitis A virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP91107526 | 1991-05-08 | ||
PCT/EP1992/001013 WO1992019268A1 (en) | 1991-05-08 | 1992-05-08 | New hepatitis a virus strain, method for the isolation of new hepatitis a virus strains and hepatitis a vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
GR3026612T3 true GR3026612T3 (en) | 1998-07-31 |
Family
ID=8206711
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR930300089T GR930300089T1 (en) | 1991-05-08 | 1993-09-30 | Hepatitis a virus strain, method for the isolation of said virus strains and hepatitis a vaccines |
GR980400808T GR3026612T3 (en) | 1991-05-08 | 1998-04-10 | Hepatitis a virus strain, method for the isolation of said virus strains and hepatitis a vaccines |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR930300089T GR930300089T1 (en) | 1991-05-08 | 1993-09-30 | Hepatitis a virus strain, method for the isolation of said virus strains and hepatitis a vaccines |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0542949B1 (el) |
JP (1) | JP3527238B2 (el) |
AT (1) | ATE163548T1 (el) |
AU (1) | AU662528B2 (el) |
CA (1) | CA2086832C (el) |
DE (2) | DE542949T1 (el) |
DK (1) | DK0542949T3 (el) |
ES (1) | ES2056780T3 (el) |
GR (2) | GR930300089T1 (el) |
WO (1) | WO1992019268A1 (el) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE205536T1 (de) * | 1992-09-18 | 2001-09-15 | Smithkline Beecham Biolog | Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe |
US5766906A (en) * | 1994-07-11 | 1998-06-16 | The University Of North Carolina At Chapel Hill | Hepatitis A virus deletion mutants and vaccine formulations containing the same |
PL1802746T3 (pl) | 2004-10-27 | 2011-10-31 | Crucell Switzerland Ag | Cząstki wirosomu zawierające antygeny wirusa grypy i wirusa zapalenia wątroby typu B |
CN116514965B (zh) * | 2023-06-15 | 2023-11-10 | 上海精翰生物科技有限公司 | 甲型肝炎病毒抗体及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2398504A1 (fr) * | 1977-07-29 | 1979-02-23 | Tours Inst Virologie | Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a |
US4164566A (en) * | 1978-08-17 | 1979-08-14 | Merck & Co., Inc. | Hepatitis a virus cell culture in vitro |
CA1164799A (en) * | 1979-09-04 | 1984-04-03 | Paula A. Giesa | Cell culture of hepatitis a virus |
-
1992
- 1992-05-08 DE DE199292910019T patent/DE542949T1/de active Pending
- 1992-05-08 AT AT92910019T patent/ATE163548T1/de active
- 1992-05-08 EP EP92910019A patent/EP0542949B1/en not_active Expired - Lifetime
- 1992-05-08 AU AU17436/92A patent/AU662528B2/en not_active Expired
- 1992-05-08 DE DE69224590T patent/DE69224590T2/de not_active Expired - Lifetime
- 1992-05-08 WO PCT/EP1992/001013 patent/WO1992019268A1/en active IP Right Grant
- 1992-05-08 ES ES92910019T patent/ES2056780T3/es not_active Expired - Lifetime
- 1992-05-08 CA CA002086832A patent/CA2086832C/en not_active Expired - Lifetime
- 1992-05-08 DK DK92910019T patent/DK0542949T3/da active
- 1992-05-08 JP JP50949692A patent/JP3527238B2/ja not_active Expired - Lifetime
-
1993
- 1993-09-30 GR GR930300089T patent/GR930300089T1/el unknown
-
1998
- 1998-04-10 GR GR980400808T patent/GR3026612T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU662528B2 (en) | 1995-09-07 |
CA2086832C (en) | 2007-05-01 |
GR930300089T1 (en) | 1993-09-30 |
EP0542949A1 (en) | 1993-05-26 |
ATE163548T1 (de) | 1998-03-15 |
ES2056780T3 (es) | 1998-08-16 |
CA2086832A1 (en) | 1992-11-09 |
ES2056780T1 (es) | 1994-10-16 |
DK0542949T3 (da) | 1998-12-07 |
AU1743692A (en) | 1992-12-21 |
DE69224590T2 (de) | 1998-10-15 |
DE542949T1 (de) | 1993-09-02 |
JP3527238B2 (ja) | 2004-05-17 |
EP0542949B1 (en) | 1998-03-04 |
JPH06500238A (ja) | 1994-01-13 |
DE69224590D1 (de) | 1998-04-09 |
WO1992019268A1 (en) | 1992-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY103182A (en) | Vaccines against acquired immune deficiency syndrome. | |
WO1993000365A3 (en) | Hepatitis c virus (hcv) polypeptides | |
EP0677533A3 (en) | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof | |
NZ219113A (en) | Hiv peptide containing epitope of the env protein | |
NO872581L (no) | Et produksjon av antistoffer ved anvendelse av insolubil iserte immunkomplekser. | |
SK495A3 (en) | Detection method of antibodies of hepatitis virus and set for detection of antibodies hcv | |
ATE127024T1 (de) | Immunogene komplexe, insbesondere iscoms. | |
OA09802A (en) | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus. | |
HK1013849A1 (en) | An augmented western blot format and immunoassay for detection of viral antibodies | |
JPS5740412A (en) | Manufacture of virus antigen | |
Weiland et al. | Development of monoclonal neutralizing antibodies against bovine viral diarrhea virus after pretreatment of mice with normal bovine cells and cyclophosphamide | |
GR930300089T1 (en) | Hepatitis a virus strain, method for the isolation of said virus strains and hepatitis a vaccines | |
SG95574A1 (en) | Immunoreactive antigens of hepatitia e virus | |
CA2080548A1 (en) | Monoclonal antibodies to hepatitis c virus | |
GB9810756D0 (en) | Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof | |
ES8802406A1 (es) | Un metodo para detectar el anticuerpo para el antigeno superficial de la hepatitis b de subtipona como divisional de la patente de invencion 545.205 del 15-7-85 | |
FR2482980B1 (el) | ||
NO953749L (no) | Hepatitt B-escapemutantspesifikke bindingsmolekyler | |
CA2095735A1 (en) | Monoclonal antibodies to hepatitis c virus and method for using same | |
PH21459A (en) | Process for assaying atl virus antibody and reagent therefor | |
DE69025629D1 (de) | Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids-verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern | |
Pervikov et al. | Improvement of methods for intratypic differentiation of polioviruses: III. Neutralization test with cross-adsorbed sera for differentiation between wild and vaccine strains of polioviruses | |
Brantschen | Hepatitis A virus strain, method for the isolation of new hepatitis A virus strains and hepatitis A vaccines | |
ES2013665A6 (es) | Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso. | |
SE8704114D0 (sv) | Monoclonal antibody, a process for its preparation and the use thereof |